key: cord-0736224-7dsjldts
authors: Hahn, William O.; Wiley, Zanthia
title: COVID-19 Vaccines
date: 2022-01-31
journal: Infect Dis Clin North Am
DOI: 10.1016/j.idc.2022.01.008
sha: 3f8db75c7d3625ce2481d9d51487e15677ca0322
doc_id: 736224
cord_uid: 7dsjldts

This manuscript is a narrative review of the rapidly moving COVID-19 vaccine field with an emphasis on clinical efficacy established in both randomized trials and post-marketing surveillance of clinically available vaccines. We review the major clinical trials that supported authorization for general use of the Janssen (Ad.26.CoV2), Pfizer-BioNTech (BNT162b2), and Moderna (mRNA-1273) vaccines and the publicly available post-marketing information with the goal of providing a broad, clinically relevant comparison of efficacy and safety. This review is primarily focused on the United States (US) market.

Within one year of the first identification of SARS-CoV-2, a series of landmark clinical trials involving a variety of vaccine approaches unequivocally demonstrated that COVID-19 was a vaccine-preventable illness [1] [2] [3] [4] [5] [6] [7] . Since the initial demonstration of clinical efficacy in the fall of 2020, several products have achieved authorization or licensure and billions of persons have been vaccinated worldwide. All vaccine candidates to date have demonstrated a high degree of efficacy against hospitalization and severe disease. However, there has been wide variation in the reported efficacy against infection and mildly symptomatic disease, and questions remain whether there are significant differences in the durability of the clinical protection elicited by various vaccine platforms. This review is an attempt to briefly summarize a fast-moving field, with an emphasis on clinical efficacy established in both randomized trials and post-marketing surveillance. Important efforts to address concerns regarding vaccine equity, including the racial and ethnic disparities associated with vaccine access, will be addressed elsewhere in Chapter 4.

Approximately six months after the initial description of a respiratory virus syndrome associated with SARS-CoV-2 infection, efficacy trials were initiated in several countries. Within 10 months several products were clinically available, which have now been administered to billions of persons worldwide. The incredible pace of the development schedule has prompted questions from the public regarding whether safety or data quality were compromised in the pursuit of speed. For reference, the shortest development cycle under modern approval mechanisms was approximately 5 years for an Ebola vaccine, and a typical vaccine approval cycle takes 10-15 years 8 ; the old paradigm for vaccine development timelines has been shattered.

The time savings during the development of COVID-19 vaccines was achieved via unparalleled degrees of public financial support and a higher tolerance for at-risk investment into the technology and process, when compared to previous vaccine development cycles. Some of the key efficiency gains were achieved by immediately initiating efficacy trials after establishing that vaccines were safe and immunogenic rather than waiting for information regarding the durability of the immune response (as would be typical). To further increase the pace of the COVID-19 vaccine trials, a large population was enrolled with a "time-to-event" trial design, whereby prespecified efficacy analysis was based upon a specific number of observed infections rather than a predefined observation period. From the implementation side, large amounts of vaccines were manufactured prior to the establishment of clinical efficacy, meaning that there was substantial risk that resources devoted to manufacturing a vaccine with unknown efficacy could have been wasted if the vaccine failed to provide clinical protection. By manufacturing a large amount of candidate vaccines prior to demonstrating these vaccines are effective, national health authorities were able to rapidly roll out massive vaccination campaigns immediately after the vaccines were shown to be clinically efficacious. It is important to note that while private industry developed and sponsored many of the trials, public dollars supported the trials, substantially decreasing the risk to a particular company from both the clinical trial and manufacturing perspectives.

The current regulatory landscape is rapidly evolving, but three vaccines have achieved emergency use authorization (EUA) in the US as of 2021: (BNT162b2 from Pfizer-BioNTech, mRNA-1273 from Moderna, and the Ad26.COV2.S product from Janssen Pharmaceuticals), The Pfizer (BNT162b2) vaccine has since achieved biologic license application (BLA) approval from the US Food and Drug Administration (FDA). All three have seen widespread implementation, with mRNA vaccines comprising most vaccinations in the US. Both the Pfizer (BNT162b2) and Moderna (mRNA-1273) vaccines comprise two doses whereas the Janssen vaccine (Ad26.COV2.S) is approved as a one dose regimen. Advanced candidate vaccines that have undergone (or are undergoing) phase III trials to support licensure in the US include products from Sanofi, Novavax, and AstraZeneca; these products are undergoing FDA regulatory review, but the approval timeline for these products has not been established as of early 2022. Other vaccines have achieved international licensure but are not, to date, conducting trials to support licensure in the US.

All vaccines to date target the spike protein of the SARS-CoV-2 virus using a variety of platforms to deliver the spike antigen, including mRNA encapsulated in lipid nanoparticles (Pfizer and Moderna), replication incompetent viruses (AstraZeneca (AZ)/University of Oxford, Janssen, Gameleya), or recombinant proteins (Novavax). Except for the AstraZeneca product, all other vaccines in advanced stages in the US use a modified spike protein designed to be more stable in the prefusion state; the AZ product uses a native sequence. There are over 50 candidate vaccines in various stages of clinical testing using a variety of approaches; the specific details of these products are beyond the scope of this review.

All phase III efficacy trials have been randomized, placebo-controlled trials with laboratory confirmed SARS-CoV-2 infection in combination with symptomatic COVID-19 disease considered the primary endpoints. The pre-specified statistical analysis plan of each trial to date conducted in the US included a minimum number of clinical endpoints that triggered an interim analysis (typically around 100-150 cases). In general, the protocols were designed assuming a much lower rate of community transmission than was observed (an assumption of ~1% of placebo recipients per year becoming infected versus an observed rate of ~5-10% per year); the high rate of community transmission was an underappreciated contributor to the rapid pace of determining that a given vaccine was effective. All of the landmark trials reported below were conducted prior to the emergence of the Delta or Omicron variants. Sanofi is currently testing their product and likely will have data from the period coinciding with the emergence of the Delta and Omicron variants.

Although it is somewhat counterintuitive given the rapid pace of vaccine approval, the COVID-19 vaccine trials generated substantially more short-term safety data than would be available during a typical vaccine approval process. For example, each of the efficacy trials intended for licensure in the US have enrolled (or plan to enroll) ~30,000 participants, with between 15,000 and 20,000 administered study product. For comparison, the RESOLVE trial, which was intended to support licensure of a vaccine against lower respiratory tract infection caused by respiratory syncytial virus in older adults only enrolled 11,856 participants with 1:1 randomization, meaning only 5,921 participants were administered study product (https://clinicaltrials.gov/ct2/show/NCT02608502).

Despite the large number of trial participants leading to abundant safety data, important safety signals for these vaccines were only determined with post-marketing surveillance after widespread implementation (see below).

The generally consistent vaccination strategy between products (with 5 of the 6 major vaccine platforms produced in the US including the same inserts of the spike protein of SARS-CoV-2) offers an unprecedented capacity for comparing the safety profile and performance across various platforms. An important technical note is the conceptual differentiation in safety outcomes between reactogenicity (transient symptoms such as malaise or arm pain, for example) and serious adverse events attributable to the vaccine (Guillain-Barre syndrome, for example). The former are quite common with all vaccines, whereas the latter are extremely rare. The CDC is actively monitoring vaccines implemented using an EUA with several postmarketing surveillance programs.

All vaccines where trial data have been reported were found to be safe and effective against both mild and severe disease (the Sanofi trial has not reported outcomes as of this writing). All vaccines used the same insert, a SARS-CoV-2 full length spike, modified with two prolines that lock the protein into a form similar to the form the protein has prior to fusion with the target host cell. Both the Moderna (mRNA 1273) and the Pfizer (BNT162b2) vaccines require an established cold chain capable of storage at -20-70 degrees C depending on the product, whereas the Janssen adenovirus vector vaccine (Ad26.COV2.S) can be stored for months in a refrigerator (4 degrees C).

While it is now incontrovertible that clinical COVID-19 can be prevented by vaccination, there are major outstanding questions about how SARS-CoV-2 will evolve in response to immune pressure from both natural immunity and immunity induced by the current generation of SARS-CoV-2 vaccines. Additionally, as new variants, such as Delta and Omicron spread, the efficacy of current vaccines against asymptomatic and mild infection, and therefore also in interrupting transmission, is less clear, even while vaccines designed against the ancestral strain retain strong effectiveness against severe disease and death.

The Moderna vaccine (mRNA-1273) product is a 100mcg dose of the SARS-CoV-2 spike protein encoded by mRNA and lipid nanoparticles (LNP), developed by Moderna and the Vaccine Research Center (VRC) within the National Institute of Health (NIH). The regimen tested was a two-dose regimen, administered with a four-week interval between doses.

Phase III Clinical Trial ("COVE" trial) ( Table 1) :

--Results from a phase 3 randomized, observer-blinded, placebo-controlled trial of the Moderna SARS-CoV-2 vaccine candidate (mRNA-1273) indicated that the vaccine showed 94.1% efficacy at preventing COVID-19 (ancestral and alpha variants), including severe disease. 30,420 volunteers were enrolled (15,210 placebo, 15,210 vaccine).

--Efficacy was similar across key secondary analyses, including in participants who had evidence of SARS-CoV-2 infection at baseline and analyses in participants 65 years of age or older.

--Serious adverse events were rare, and the incidence was similar to placebo.

--Reactogenicity after one dose was generally mild-to-moderate with pain reported as the most common injection-site symptom. For systemic reactogenicity symptoms, 54.9% of participants reported solicited adverse events after the first dose (compared to 42.2% of placebo) and this increased to 79.4% with the second dose (compared to 36.5% with placebo). To place this rate in context with other vaccines, the rate of systemic reactogenicity after the first dose is less than that observed for the recombinant adjuvanted zoster vaccine and after the second mRNA-1273 dose is similar. 9 The Shingrix vaccine is a licensed vaccine generally considered to have a "moderate" degree of reactogenicity. J o u r n a l P r e -p r o o f

The Pfizer product (BNT162b2) is a 30 mcg dose of the SARS-CoV2 spike protein encoded by mRNA and encapsulated with lipid nanoparticles (LNP), developed by BioNTech and Pfizer. The regimen tested was a two-dose regimen, administered with a three-week interval between doses.

Results of the phase 3 double-blind, randomized, placebo-controlled trial for the BioNTech and Pfizer mRNA vaccine (BNT162b2) (n=21,720 in vaccine group, and 21,728 in placebo group) showed a vaccine efficacy of 95% (95% CI 90.3-97.6) against ancestral strain and Alpha variant, with 8 cases of COVID-19 (1 severe case) in the vaccine group and 162 cases (9 severe cases) in the placebo group (Table 2) .

Efficacy was similar across subgroups defined by age, sex, race, ethnicity, body-mass index, and presence of co-existing conditions.

Mild-to-moderate reactogenicity was commonly observed and more frequent with the second dose. Severe fatigue was observed in approximately 4% of Pfizer (BNT162b2) recipients.

Few participants in either group had severe or serious adverse events, and the 6 deaths (2 in vaccine group, 4 in placebo group) were determined by investigators not to be related to the vaccine or placebo by investigators. Janssen (Ad26.COV2.S)

The Janssen (pharmaceutical division of Johnson and Johnson) vaccine product was tested as single-dose regimen in the Ensemble trial ( Table 3 ). The vaccine includes the same insert as the Pfizer (BNT162b2) and Moderna (mRNA-1273) products but uses a well-established replication incompetent adenovirus (Ad26) as a delivery package. The trial was conducted internationally, with 44% of participants enrolled in the US, 41% of participants enrolled in South America, and 15% in South Africa. Of note, unlike either the Moderna (mRNA-1273) or Pfizer (BNT162b2) trial, the timing of the ENSEMBLE trial coincided with the emergence of the beta variant (B1.351) in South Africa 3 . Since the vaccine was administered as a one-dose regimen, data regarding protection both 14 days and 28 days (more analogous to the mRNA trials) after administration are presented. The level of protection against moderate to severe COVID-19 infection was 72% in the United States, 66% in Latin America, and 57% in South Africa 28 days post-vaccination. Molecular sequencing of the breakthrough cases suggests a much higher presence of the beta variant in breakthrough cases, in line with the reported epidemiology of the pandemic in South Africa.

Anaphylaxis has been rarely observed following vaccination with the mRNA vaccines. In one post-marketing study, 21 cases of anaphylaxis were determined to be related to vaccination (a rate of 11.1 per million doses administered), including 17 in people with prior documented history of allergies/allergic reactions, 7 of whom had a prior history of anaphylaxis. The median interval from vaccine receipt to symptom onset was 13 minutes 10 . The incidence of acute allergic reactions in healthcare workers (HCW) who received mRNA COVID-10 vaccines from December 16, 2020 -February 12, 2021 was assessed in a prospective observational cohort study conducted in Boston, Massachusetts. Of HCW who received an mRNA COVID-19 vaccine and completed a symptom survey, 98% had no symptoms of an allergic reaction (different from true anaphylaxis). Acute allergic reactions were slightly more frequent with the Moderna vaccine (mRNA-1273) (2.20%) compared with Pfizer (BNT162b2) (1.95%) and anaphylaxis occurred at a rate of 2.47 cases per 100,000 vaccinations (similar rates between the Moderna (mRNA-1273) and Pfizer (BNT162b2)). Anaphylaxis was confirmed in 16 HCW, of whom 63% (n = 10) reported prior allergic reaction and 31% (n = 5) reported prior anaphylaxis 11 .

Another study performed analysis of safety surveillance data from Vaccine Safety Datalink of 10 The current hypothesis is that the reaction is to polyethylene glycol, a preservative used in the vaccines. Persons with a history of hypersensitivity to polyethylene glycol or anaphylaxis to the first dose of an mRNA series should be vaccinated with an alternate product, such as the Janssen (Ad26.COV2.S) vaccine. Similarly, rare persons are known to have severe allergies to polysorbate-present in the Janssen adenovirus vaccine-and these individuals should be vaccinated with an mRNA vaccine.

Additionally, there are a wide range of rashes and other skin findings associated with mRNA vaccine administration. None of these are life-threatening. One notable finding with the mRNA vaccine is a delayed, local reaction where substantial erythema/induration is observed at the injection site on or around day 8 post-vaccine administration. These do not represent true allergy and patients have safely received repeat vaccinations.

• Allergic reactions occur median 15 minutes after product administration • No cross-reactivity between mRNA and adenoviral vectors, so even a person with documented allergy should be eligible for continuing the series or boosting with an alternative product.

• Delayed injections site reactions (onset on or after day 8) have been reported in ~0.5-1% of participants after the first dose; subsequent doses are well tolerated and therefore delayed injection site reactions are not a contraindication to booster doses.

Several studies have reported the rare diagnoses of myocarditis following the COVID-19 mRNA vaccines, typically in young men and adolescent boys. One population-based cohort study of 2,292,924 individuals (median age 49 years old) who received at least 1 dose of COVID-19 mRNA vaccines, acute myocarditis was rare, at an incidence of 5. 15 . Data from the largest health care organization in Israel to evaluate the safety of the Pfizer vaccine (BNT162b2) also noted an excess risk of myocarditis in the vaccinated. The control and vaccinated groups each included a mean of 884,828 persons and vaccination was most strongly associated with an elevated risk of myocarditis (risk ratio, 3.24; 95% CI, 1.55 to 12.44).

It is important to note that SARS-CoV-2 infection itself is much more strongly associated with increased risk of myocarditis (risk ratio 18.28; 95% CI, 3.95 to 25.12) with an excess risk of myocarditis (1 to 5 events per 100,000 persons) 16 . Another study of more than 2.5 million vaccinated persons (who were >16 years old) in this same large healthcare system, 54 cases met the criteria for myocarditis. Of those who received at least one dose of the Pfizer (BNT162b2) vaccine, the estimated incidence of myocarditis was 2.13 cases per 100,000 persons; the highest incidence was among male patients between the ages of 16 and 29 years (10.69 cases per 100,000 persons). Most cases of myocarditis were mild or moderate in severity 17 . Although the rare risk of myocarditis with mRNA vaccines has been reported, the known risk of morbidity, including cardiac injury and myocarditis, following COVID-19 infection should be taken into consideration 15 .

• Risk of myocarditis with COVID-19 infection is higher than with COVID-19 vaccination.

• Myocarditis risk is highest the first week after a second dose of mRNA vaccine.

Cerebral venous sinus thrombosis (CVST) associated with severe thrombocytopenia and disseminated intravascular coagulation that resembles autoimmune heparin-induced thrombocytopenia has been reported in recipients of the Janssen (Ad26.COV2.S) vaccine and recipients of the AstraZeneca vaccine (AZD1222 (ChAdOx1-S nCCoV-19 18 . On April 23, 2021, the CDC and the FDA recommended that the use of Janssen (Ad26.COV2.S) vaccines resume in the US, noting that the potential benefits of the vaccine outweighs the potential and known risks 19 . They also noted that women under the age of 50 years should be made aware of alternative COVID-19 vaccine options for which this risk has not been seen and should be made aware of the rare, but increased, risk for CVST. For these reasons, the CDC generally recommends use of mRNA vaccines over the Janssen (Ad26.COV2.S) product in most situations.

• Even with extremely low risk of vaccine induced thrombosis and thrombocytopenia (VITT) due to adenovirus vectored vaccines, women under age 50 should be made aware of mRNA vaccines if available.

• The CDC currently recommends mRNA vaccines over Janssen (Ad26.COV2.S) based upon the differences in safety profile

The US FDA also identified a potential safety concern for Guillain-Barre syndrome (GBS) following Janssen (Ad26.COV2.S) vaccination 20 person-years. For both risk windows, the observed to expected rate ratio was elevated in all age groups except persons aged 18 through 29 years. These findings suggest a small but statistically significant safety concern for GBS following receipt of the Janssen (Ad26.COV2.S) vaccine 20 . Notably, this increase in risk is less than the increased risk of GBS observed following natural SARS-CoV-2 infection 21

• Risk of Guillain-Barre is higher with natural SARS-CoV-2 infection than with vaccination with adenovirus vectored vaccines.

mRNA vaccines Adults over 50 years of age.

High mRNA vaccine effectiveness among older adults has been reported. A common approach to establishing efficacy in a real-world setting is a "test-negative" design. In this approach, patients tested clinically for SARS-CoV-2 infection are compared with those who tested negative. These analyses are relatively easy to conduct, but one potential criticism is that the underlying indication for testing can change based upon the population (e.g. asymptomatic screening versus patients presenting with upper respiratory symptoms). A study of adults (> 50 years-old) with COVID-19-like illness who underwent SARS-CoV-2 molecular testing evaluated 41,552 hospital admissions and 21,522 visits to emergency department or urgent care clinics in multiple states from January 1 through June 22, 2021. The effectiveness of full mRNA vaccination (> 14 days after the second dose) was 89% against laboratory-confirmed SARS-CoV-2 infection leading to hospitalization, 90% against infection leading to an ICU admission, and 91% against infection leading to an emergency department or urgent care clinic visit (against ancestral or Alpha strains). The effectiveness of full vaccination with respect to a COVID-19-associated hospitalization or emergency department or urgent care clinic visit was similar with the Pfizer (BNT162b2) and Moderna (mRNA-1273) vaccines and ranged from 81% to 95% among adults > 85 years old, those with chronic medical conditions, and Black or Hispanic adults 22 . Another study found that among adults aged 65-74 years, effectiveness of full vaccination for preventing hospitalization was 96% for Pfizer (BNT162b2) and 96% for Moderna (mRNA-1273) and among adults > 75 years old, effectiveness of full vaccination for preventing hospitalizations was 91% for Pfizer (BNT162b2) and 96% for Moderna (mRNA-1273) 23 .

One early study was conducted during a nationwide mass vaccination in Israel's largest healthcare organization of persons newly vaccinated with Pfizer (BNT162b2) between December 20, 2020-February 

The initial large-scale vaccinations against COVID-19 occurred less than one year prior to the drafting of this publication. Data regarding the long-term durability of clinical protection are rapidly emerging. Nevertheless, it has been repeatedly observed that neutralizing antibody titers wane, albeit with some variation by product. Titers induced by the Janssen (Ad26.COV2.S) vaccine appear lower but more stable over time, whereas neutralizing titers induced by the mRNA vaccines are initially higher but appear to decline with a steeper slope 31 . There appear to be subtle differences in the durability of clinical protection, with the Moderna (mRNA-1273) vaccine appearing to provide a slightly longer period of protection when compared to the Pfizer (BNT162b2) or Janssen (Ad26.COV2.S) vaccines 32 . Neutralizing antibody titers were a clear surrogate of protection observed in the initial randomized trial of the Moderna (mRNA-1273) product 33 . In combination with the observation that there are emerging data suggesting a waning of clinical immunity 32 and the observation that boosting with any product leads to an increase in antibody titers 34 , a mass-scale booster program was initiated in the US toward the end of 2021.

The FDA authorized a booster dose for all persons regardless of primary series. Additionally, the CDC does not differentiate their recommendations for a booster based the initial product or platform. Finally, it is important to note the approved dose of the booster is different than the dose approved for the primary series with respect to the Moderna (mRNA-1273) vaccine, where the dose is half of the initial dose. The Pfizer (BNT162b2) dose is the same as the primary series and the Janssen booster (Ad26.COV2.S) is the same dose as the initial series. The reduced dose of the mRNA was selected to relieve pressure on manufacturing capacity and also to potentially reduce reactogenicity.

The degree of clinical protection against COVID-19 provided by vaccination remains an incredible triumph of modern science. Analysis of data generated from "real-world" vaccination cohorts have recapitulated the striking degree of efficacy of vaccination against clinical disease, especially severe disease, observed in randomized controlled trials. Extremely rare severe adverse events, such as myocarditis, are much more likely to occur with clinical COVID-19 than after vaccination. Even for persons with documented anaphylaxis to a vaccine component, alternative vaccination strategies exist. While there may be subtle differences with respect to the duration of protection against mild illness conferred by various vaccine products, these differences pale in comparison to the difference between the unvaccinated or those with only immunity following natural infection. The emergence of the Omicron variant has been associated with substantial immune escape and the full degree of loss-of-protection against clinical disease is not yet clear at the time this manuscript was prepared. It is clear, however, that substantial protection against severe disease has been maintained with vaccination and it is clear that vaccination remains the best method for preventing severe disease.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States

Acute Allergic Reactions to mRNA COVID-19 Vaccines

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older

Coronavirus Disease 2019 and the Athletic Heart: Emerging Perspectives on Pathology, Risks, and Return to Play

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination

Recommends Use of Johnson & Johnson's Janssen COVID-19 Vaccine Resume

Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome

Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years -COVID-NET, 13 States

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalization -Five Veterans Affairs Medical Centers

Comparative Effectiveness of Moderna

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines

Breakthrough SARS-CoV-2 infections after vaccination in North Carolina. bioRxiv

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv

Heterologous SARS-CoV-2 Booster Vaccinations -Preliminary Report. medRxiv